IN2012DN01225A - - Google Patents

Info

Publication number
IN2012DN01225A
IN2012DN01225A IN1225DEN2012A IN2012DN01225A IN 2012DN01225 A IN2012DN01225 A IN 2012DN01225A IN 1225DEN2012 A IN1225DEN2012 A IN 1225DEN2012A IN 2012DN01225 A IN2012DN01225 A IN 2012DN01225A
Authority
IN
India
Prior art keywords
active ingredient
polyisobutylene
layer
fentanyl
plasticizer
Prior art date
Application number
Inventor
Nouha Salman
Bjorn Schurad
Ingo Teutsch
Original Assignee
Acino Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41559211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Ag filed Critical Acino Ag
Publication of IN2012DN01225A publication Critical patent/IN2012DN01225A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a transdermal therapeutic system for administering an active ingredient through the skin comprising: a) a back layer, b) a reservoir on the back layer comprising b1) a first layer containing active ingredient, at least one gel former, at least one plasticizer, and a first polyisobutylene; and b2) a second layer containing active ingredient, at least one gel former, at least one plasticizer, and a second polyisobutylene, wherein the first polyisobutylene is different from the second polyisobutylene, wherein at least the first layer contains undissolved active ingredient in the form of active ingredient particles; and wherein the active ingredient is fentanyl or an analogue of the fentanyl.
IN1225DEN2012 2009-09-14 2010-09-14 IN2012DN01225A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170223A EP2295046B1 (en) 2009-09-14 2009-09-14 Transdermal therapeutic system for application of fentanyl or an analogue material thereof
PCT/EP2010/063433 WO2011029948A2 (en) 2009-09-14 2010-09-14 Transdermal therapeutic system for administering fentanyl or an analogue thereof

Publications (1)

Publication Number Publication Date
IN2012DN01225A true IN2012DN01225A (en) 2015-04-10

Family

ID=41559211

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1225DEN2012 IN2012DN01225A (en) 2009-09-14 2010-09-14

Country Status (10)

Country Link
US (1) US20120209223A1 (en)
EP (2) EP2295046B1 (en)
JP (1) JP2013504546A (en)
CN (1) CN102548546A (en)
AU (1) AU2010294160A1 (en)
BR (1) BR112012005629A2 (en)
CA (1) CA2773008A1 (en)
IN (1) IN2012DN01225A (en)
MX (1) MX2012002727A (en)
WO (1) WO2011029948A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5558074B2 (en) * 2009-10-15 2014-07-23 日東電工株式会社 Coating film protection sheet
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
EP2599478A1 (en) * 2011-11-30 2013-06-05 Acino AG Transdermal therapeutic system for application of fentanyl or an analogue material thereof
US9072682B2 (en) * 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
CN104825426A (en) * 2015-05-26 2015-08-12 韩晓明 Double-phase melatonin patch
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
US10377114B2 (en) * 2017-04-20 2019-08-13 Inep Europe Sarl Method for making a transdermal fentanyl patch with even drug crystal distribution
WO2018194879A1 (en) * 2017-04-19 2018-10-25 Inep Europe Sarl Method for making a transdermal fentanyl patch with even drug crystal distribution
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
CN111419827B (en) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 Pharmaceutical composition for alfentanil transdermal administration and preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19830898A1 (en) 1998-07-10 2000-01-13 Hexal Ag Device for improving the removal ability of flat, substrate-packed sections packed in pouches with a pressure-sensitive adhesive
SE9803239D0 (en) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
WO2001064149A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
NZ528148A (en) 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
AU2003272878A1 (en) 2002-09-13 2004-04-30 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
CN1640387A (en) * 2004-01-15 2005-07-20 财团法人工业技术研究院 Intradermal absorbing paster and its preparing method
US9205062B2 (en) * 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
EP1625854B1 (en) 2004-08-09 2008-10-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Albumin conjugates containing a glucuronic linker
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
WO2008007554A1 (en) * 2006-07-14 2008-01-17 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation

Also Published As

Publication number Publication date
JP2013504546A (en) 2013-02-07
EP2295046A1 (en) 2011-03-16
WO2011029948A2 (en) 2011-03-17
AU2010294160A1 (en) 2012-04-05
WO2011029948A3 (en) 2011-10-13
EP2477616B1 (en) 2013-08-14
CN102548546A (en) 2012-07-04
EP2295046B1 (en) 2012-12-19
US20120209223A1 (en) 2012-08-16
EP2477616A2 (en) 2012-07-25
MX2012002727A (en) 2012-05-08
BR112012005629A2 (en) 2016-08-02
CA2773008A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
IN2012DN01225A (en)
MY163809A (en) Transdermal drug delivery system containing donepezil
MY183873A (en) Transdermal therapeutic system for application of an agent
MX2009012273A (en) Transdermal delivery devices assuring an improved release of an active principle through a biological interface.
WO2011076621A3 (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
MX347195B (en) Transdermal drug delivery system and method of using the same.
MX2009013574A (en) Modified release solid or semi-solid dosage forms.
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
MX2022008277A (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof.
MX2016008138A (en) System for the transdermal delivery of active ingredient.
EA200801575A1 (en) TRANSDERMAL SUPPLY MEPTASINOLA
MX366230B (en) Multi-polymer compositions for transdermal drug delivery.
IN2014DN09817A (en)
MX2012008381A (en) Dental strip for administration of oral treatment.
EA201400628A1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR THE INTRODUCTION OF FENTANILE OR ITS ANALOGUE
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
EA201300648A1 (en) TRANSDERMAL THERAPEUTIC SYSTEM (TTS) CONTAINING ROTIGOTIN
AU2014203502B2 (en) Once-a-day replacement transdermal administration of fentanyl
NZ595549A (en) Transdermal therapeutic system containing nicotine
WO2012111996A3 (en) Transdermal delivery system containing galantamine or salts thereof
BR112012014107B8 (en) transdermal therapeutic system (tts) and tts production process
WO2016149077A3 (en) Fentanyl transdermal delivery system
MX2021012709A (en) Transdermal therapeutic system.
MX2015010967A (en) Transdermal formulations of laquinimod.